Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

BACKGROUND: Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT(1F) receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on migraine disability assessed with the Migraine Disability A...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Lombard, Louise, Ruff, Dustin D., Krege, John H., Loo, Li Shen, Buchanan, Andrew, Melby, Thomas E., Buse, Dawn C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041198/
https://www.ncbi.nlm.nih.gov/pubmed/32093628
http://dx.doi.org/10.1186/s10194-020-01088-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041198/
https://www.ncbi.nlm.nih.gov/pubmed/32093628
http://dx.doi.org/10.1186/s10194-020-01088-4

Ejemplares similares